← Back to Search

Muscarinic Receptor Antagonist

CVL-231 for Schizophrenia

Phase 1
Waitlist Available
Research Sponsored by Cerevel Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening, day-1 (t=1hour), day-1 (t=1.5hour), day-1, day 1 (t=0hour), day 1(t=1.5hour), day 1 (t=3hour), day 1 (t=6hr), day 1 (t=8.0), day 2 (t-=24hr), day 10
Awards & highlights

Study Summary

This trial will test how well a new drug called CVL-231 binds to muscarinic receptors type 4 in the brain, after it is taken by mouth.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening, day-1 (t=1hour), day-1 (t=1.5hour), day-1, day 1 (t=0hour), day 1(t=1.5hour), day 1 (t=3hour), day 1 (t=6hr), day 1 (t=8.0), day 2 (t-=24hr), day 10
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening, day-1 (t=1hour), day-1 (t=1.5hour), day-1, day 1 (t=0hour), day 1(t=1.5hour), day 1 (t=3hour), day 1 (t=6hr), day 1 (t=8.0), day 2 (t-=24hr), day 10 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
M4 receptor occupancy in the striatum following single oral doses of CVL-231 in healthy adult subjects
Secondary outcome measures
AUCscan duration for CVL-231
Cavg/Scan duration for CVL-231
Cmax during scan for CVL-231
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CVL-231Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CVL-231
2022
Completed Phase 1
~300

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Cerevel Therapeutics, LLCLead Sponsor
35 Previous Clinical Trials
5,700 Total Patients Enrolled
7 Trials studying Schizophrenia
2,011 Patients Enrolled for Schizophrenia
Matthew Leoni, MD, MBAStudy DirectorCerevel Therapeutics, LLC
2 Previous Clinical Trials
89 Total Patients Enrolled
1 Trials studying Schizophrenia
16 Patients Enrolled for Schizophrenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the scope of enrollees for this experiment?

"Absolutely, according to the details on clinicaltrials.gov, this trial is currently recruiting participants. It was first unveiled on June 1st 2021 and was most recently updated July 6th 2022. They are looking for 15 individuals at one site in particular."

Answered by AI

What potential risks come with utilizing CVL-231 as a treatment?

"Due to the minimal clinical data available, CVL-231 is judged as being low risk with a score of 1 on our Power scale. This judgement comes from it being in its initial testing phase (Phase 1)."

Answered by AI

Is registration open for this experiment at the moment?

"According to the information available on clinicaltrials.gov, this trial is actively seeking participants. The protocol was first advertised in June 2021 and revised most recently in July 2022."

Answered by AI

What criteria must an individual meet in order to be accepted as a participant of this research project?

"15 people are being sought who have been diagnosed with schizophrenia, and whose age falls between 18-55. To qualify for this trial, these criteria must be met."

Answered by AI

Is the eligibility for this medical research restricted to individuals under 18?

"The age range of this research project is between 18 years and 55 years."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
2021. "PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04787302.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top